- Home
- HBT vs BCAX Comparison
HBT vs BCAX Comparison
Compare HBT & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBT
- BCAX
- Stock Information
- Founded
- HBT 1920
- BCAX 2018
- Country
- HBT United States
- BCAX United States
- Employees
- HBT N/A
- BCAX N/A
- Industry
- HBT Major Banks
- BCAX
- Sector
- HBT Finance
- BCAX
- Exchange
- HBT Nasdaq
- BCAX NYSE
- Market Cap
- HBT 693.0M
- BCAX 670.9M
- IPO Year
- HBT 2019
- BCAX 2024
- Fundamental
- Price
- HBT $21.99
- BCAX $12.16
- Analyst Decision
- HBT Hold
- BCAX Buy
- Analyst Count
- HBT 5
- BCAX 7
- Target Price
- HBT $24.80
- BCAX $29.67
- AVG Volume (30 Days)
- HBT 44.6K
- BCAX 516.6K
- Earning Date
- HBT 04-21-2025
- BCAX 05-16-2025
- Dividend Yield
- HBT 3.82%
- BCAX N/A
- EPS Growth
- HBT 9.18
- BCAX N/A
- EPS
- HBT 2.26
- BCAX N/A
- Revenue
- HBT $221,390,000.00
- BCAX N/A
- Revenue This Year
- HBT $7.01
- BCAX N/A
- Revenue Next Year
- HBT $2.71
- BCAX N/A
- P/E Ratio
- HBT $9.73
- BCAX N/A
- Revenue Growth
- HBT N/A
- BCAX N/A
- 52 Week Low
- HBT $18.01
- BCAX $8.91
- 52 Week High
- HBT $26.25
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- HBT 46.15
- BCAX N/A
- Support Level
- HBT $21.29
- BCAX N/A
- Resistance Level
- HBT $22.31
- BCAX N/A
- Average True Range (ATR)
- HBT 0.97
- BCAX 0.00
- MACD
- HBT 0.09
- BCAX 0.00
- Stochastic Oscillator
- HBT 75.98
- BCAX 0.00
About HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.